Preparation and characterization of insulin chitosan-nanoparticles loaded in buccal films

Al-Nemrawi, Nusaiba K.; Alsharif, Sara S M; Alzoubi, Karem H.; Alkhatib, Rami

doi:10.1080/10837450.2019.1619183

Cited by 46 publications

(35 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, chitosan oligosaccharide has been applied for drug delivery system in diabetes. For instance, chitosan-microcapsulated insulin, chitosan-stabilized selenium nanoparticles, chitosan encapsulated resveratrol, chitosan coating of TiO 2 nanotube arrays for metformin, chitosan nanoparticle and chitosan hydrogel were used for improving diabetic therapy [134][135][136][137][138][139][140][141][142]. Interestingly, the development of chitosan oligosaccharide as a drug or supplement for diabetic treatment has been studied for a decade.…”

Section: Endocrinological Diseases and Diabetes Mellitusmentioning

confidence: 99%

Chitin and Chitosan Derivatives as Biomaterial Resources for Biological and Biomedical Applications

Satitsri

Muanprasat

2020

Molecules

View full text Add to dashboard Cite

Chitin is a long-chain polymer of N-acetyl-glucosamine, which is regularly found in the exoskeleton of arthropods including insects, shellfish and the cell wall of fungi. It has been known that chitin can be used for biological and biomedical applications, especially as a biomaterial for tissue repairing, encapsulating drug for drug delivery. However, chitin has been postulated as an inducer of proinflammatory cytokines and certain diseases including asthma. Likewise, chitosan, a long-chain polymer of N-acetyl-glucosamine and d-glucosamine derived from chitin deacetylation, and chitosan oligosaccharide, a short chain polymer, have been known for their potential therapeutic effects, including anti-inflammatory, antioxidant, antidiarrheal, and anti-Alzheimer effects. This review summarizes potential utilization and limitation of chitin, chitosan and chitosan oligosaccharide in a variety of diseases. Furthermore, future direction of research and development of chitin, chitosan, and chitosan oligosaccharide for biomedical applications is discussed.

show abstract

Section: Endocrinological Diseases and Diabetes Mellitusmentioning

confidence: 99%

Chitin and Chitosan Derivatives as Biomaterial Resources for Biological and Biomedical Applications

Satitsri

Muanprasat

2020

Molecules

View full text Add to dashboard Cite

show abstract

“…Nanoparticulate dosage forms differ from conventional dosage forms by loading the drug or active compound into nanoparticles prior to dispersion in a formulation base. They have been incorporated into various dosage forms for sublingual and buccal drug delivery, including gels (Marques et al, 2017), sprays (Baltzley et al, 2018), tablets (Gavin et al, 2015; El-Nahas et al, 2017), films (Giovino et al, 2013; Mortazavian et al, 2014; Al-Dhubiab et al, 2016; Masek et al, 2017; Castro et al, 2018a; Mahdizadeh Barzoki et al, 2018; Al-Nemrawi et al, 2019), and patches (Mahdizadeh Barzoki et al, 2016). These nanoparticulate formulations have been shown to: (i) improve drug permeability across the epithelium; (ii) modify drug release kinetics (e.g., controlled release or sustained release); (iii) provide solubilization (i.e., to deliver compounds which have physicochemical properties that strongly limit their aqueous solubility); and/or (iv) protect compounds that are sensitive to degradation (e.g., peptides) (Morales and Brayden, 2017; Hua et al, 2018).…”

Section: Nanoparticulate Drug Delivery Approachesmentioning

confidence: 99%

“…The majority of the studies have demonstrated sustained drug release from the nanoparticles embedded in the dosage form, with the drug then being diffused into the formulation base and absorbed into the adhered mucosa. These include nanoparticles incorporated into gels (Marques et al, 2017), sprays (Baltzley et al, 2018), tablets (Gavin et al, 2015; El-Nahas et al, 2017), films (Giovino et al, 2013; Mazzarino et al, 2014; Mortazavian et al, 2014; Al-Dhubiab et al, 2016; Masek et al, 2017; Castro et al, 2018a; Mahdizadeh Barzoki et al, 2018; Al-Nemrawi et al, 2019), and patches (Mahdizadeh Barzoki et al, 2016). Very few studies have demonstrated release of nanoparticles from the formulation base and mucosal penetration of intact nanoparticles for drug delivery (Mortazavian et al, 2014; Masek et al, 2017).…”

Section: Nanoparticulate Drug Delivery Approachesmentioning

confidence: 99%

Advances in Nanoparticulate Drug Delivery Approaches for Sublingual and Buccal Administration

Hua¹

2019

Front. Pharmacol.

131

View full text Add to dashboard Cite

The sublingual and buccal routes of administration have significant advantages for both local and systemic drug delivery. They have shown to be an effective alternative to the traditional oral route, especially when fast onset of action is required. Drugs can be rapidly and directly absorbed into the systemic circulation via venous drainage to the superior vena cava. Therefore, they are useful for drugs that undergo high hepatic clearance or degradation in the gastrointestinal tract, and for patients that have swallowing difficulties. Drugs administered via the sublingual and buccal routes are traditionally formulated as solid dosage forms (e.g., tablets, wafers, films, and patches), liquid dosage forms (e.g., sprays and drops), and semi-solid dosage forms (e.g., gels). Conventional dosage forms are commonly affected by physiological factors, which can reduce the contact of the formulation with the mucosa and lead to unpredictable drug absorption. There have been a number of advances in formulation development to improve the retention and absorption of drugs in the buccal and sublingual regions. This review will focus on the physiological aspects that influence buccal and sublingual drug delivery and the advances in nanoparticulate drug delivery approaches for sublingual and buccal administration. The clinical development pipeline with formulations approved and in clinical trials will also be addressed.

show abstract

“…Chitosan nanoparticles were prepared as described in previous publications [21,22]. Then, 8 mg of chitosan nanoparticles were dissolved in 4 mL of an aqueous solution of acetic acid (1% v/v) and the pH value of the resulting solution was 3.4.…”

Section: Preparation Of Insulin-loaded Chitosan Nanoparticles Ins-csnpsmentioning

confidence: 99%

Characterization and Efficacy of A Novel Formula of Insulin Chitosan Layered Duple Hydroxide-Nanohybrid for Oral Administration

El-Shahawy¹,

Abdel-Moneim²,

Eldin³

et al. 2020

Nano BioMed ENG

View full text Add to dashboard Cite

The development of an oral insulin therapy remains an ultimate goal to both enhance ease of use, and to provide therapeutic advantages rooted in its direct delivery to the portal vein and liver. The current study aimed to develop a novel formula for insulin oral administration against experimental diabetes in rats. Entrapped insulin (INS) between chitosan nanoparticles (CSNPs) and layered duple hydroxide (LDH) (LDH-INS-CSNPs) was chemically prepared, and characterized by X-ray diffraction, Fourier transformation infrared, high-resolution transmission electron microscope, field emission scanning electron microscope and Zeta potential measurements. The insulin release study was conducted in vitro, while the oral hypoglycemic effect of LDH-INS-CSNPs was investigated in vivo in diabetic rats. The prepared formulas revealed a variation in the spectra of characterization methods. The insulin entrapment between LDH and chitosan avoided the burst release of insulin and acid denaturation in the stomach and enzymatic degradation throughout the gut. Consequently, the blood glucose level of LDH-INS-CSNPs formula exhibited a marked hypoglycemic effect. The present work showed that the LDH-INS-CSNPs formula had a protective effect against enzymatic degradation, reduced insulin initial burst release, and enhanced bioavailability through the oral administration route. Interestingly, the presented formula could be an oral antidiabetic agent alternative to injectable insulin.

show abstract

Preparation and characterization of insulin chitosan-nanoparticles loaded in buccal films

Cited by 46 publications

References 31 publications

Chitin and Chitosan Derivatives as Biomaterial Resources for Biological and Biomedical Applications

Chitin and Chitosan Derivatives as Biomaterial Resources for Biological and Biomedical Applications

Advances in Nanoparticulate Drug Delivery Approaches for Sublingual and Buccal Administration

Characterization and Efficacy of A Novel Formula of Insulin Chitosan Layered Duple Hydroxide-Nanohybrid for Oral Administration

Contact Info

Product

Resources

About